Use as directed: Navigating the complexities of pharmaceutical trademarks

The global market for pharmaceutical products reached $1.2 trillion in 2018 – up $100 billion from the prior year. This is projected to reach $1.5 trillion by 2021.

New developments in biotechnology, nanotechnology and digital medicine are rapidly transforming the definition of pharma products. These trends are creating an ever-more crowded and complex brand landscape.

As follow up to a recent webinar of the same title, Use as directed covers the regulatory complexities specific to the pharmaceutical trademark landscape. In this white paper, Maury M. Tepper, III of IP law firm Tepper & Eyster, and Emmanuelle Ragon, Senior Legal Director and Head of Trade Marks at pharmaceutical company Sanofi, discuss the unique challenges facing pharmaceutical brands and strategies for developing and clearing pharma trademarks.